



NUPROMIC®

Artículos científicos de
Beta Defense – Beta Glucano de Levadura

Artículos científicos

- [1] Thompson, I. J., Oyston, P. C. F., Williamson, D. E., Potential of the β -glucans to enhance innate resistance to biological agents. *Exp. Rev. Anti-Inf. Ther.* 2010, 8, 339–352.
- [2] Barsanti, L., Passarelli, V., Evangelista, V., Frassanito, A. M. et al., Chemistry, physico-chemistry and applications linked to biological activities of [β]-glucans. *Nat. Prod. Report.* 2011, 28, 457–466.
- [3] Stone, B. A., Cellulose and callose: evolutionary considerations. *Abstr. Papers Am. Chem. Soc.* 2004, 227, U289–U289.
- [4] Valluri, J. V., Soltes, E. J., Callose formation during wound-inoculated reaction of *Pinus elliotii* to *Fusarium*-subglutinans. *Phytochemistry* 1990, 29, 71–72.
- [5] Legras, J. L., Merdinoglu, D., Cornuet, J. M., Karst, F., Bread, beer and wine: *Saccharomyces cerevisiae* diversity reflects human history. *Mol. Ecol.* 2007, 16, 2091–2102.
- [6] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the safety of “yeast beta-glucans” as a novel food ingredient. *EFSA J.* 2011, 9, 2137.
- [7] Von Dungern, E. F., Beiträge zur Immunitätslehr. *Münch. Med. Wochenschr.* 1900, 47, 677–680.
- [8] Pillemer, L., Ecker, E. E., Anticomplementary factor in fresh yeast. *J. Biol. Chem.* 1941, 137, 139–142.
- [9] Di Carlo, F. J., Fiore, J. V., On the composition of Zymosan. *Science* 1958, 127, 756–757.
- [10] Brown, G. D., Gordon, S., Immune recognition – A new receptor for beta-glucans. *Nature* 2001, 413, 36–37.
- [11] Xia, Y., Vetvicka, V., Yan, J., Hanikyrová, M. et al., The β -glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. *J. Immunol.* 1999, 162, 2281–2290.
- [12] Sze, D. M. Y., Chan, G. C. F., Effects of beta-glucans on different immune cell populations and cancers. *Adv. Bot. Res.* 2012, 62, 179–196.
- [13] Novak, M., Vetvicka, V., Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. *J. Immunotoxicol.* 2008, 5, 47–57.

- [14] Manners, D. J., Masson, A. J., Patterso, J. C., Structure of beta-(1–3)-D-glucan from yeast cell walls. *Biochem. J.* 1973, 135, 19–30.
- [15] Rieder, A., Samuelson, A. B. C., Do cereal mixed-linked beta-glucans possess immune-modulating activities? *Mol. Nutr. Food Res.* 2012, 56, 536–547.
- [16] Kollar, R., Reinhold, B. B., Petrakova, E., Yeh, H. J. C. et al., Architecture of the yeast cell wall – beta(1->6)-glucan interconnects mannoprotein, beta(1–3)-glucan, and chitin. *J. Biol. Chem.* 1997, 272, 17762–17775.
- [17] Ohno, N., in: Kamerling, J.P. (Ed.), *Yeast and Fungal Polysaccharides, Analysis of Glycans Polysaccharide Functional Properties, Comprehensive Glycoscience, Vol. 2*, Elsevier, Oxford 2007, pp. 559–577.
- [18] Ha, C. H., Lim, K. H., Kim, Y. T., Lim, S. T. et al., Analysis of alkali-soluble glucan produced by *Saccharomyces cerevisiae* wild-type and mutants. *Appl. Microbiol. Biotechnol.* 2002, 58, 370–377.
- [19] Amanianda, V., Clavaud, C., Simenel, C., Fontaine, T. et al., Cell wall beta-(1,6)-glucan of *Saccharomyces cerevisiae*. Structural characterization and in situ synthesis. *J. Biol. Chem.* 2009, 284, 13401–13412.
- [20] Yu, L. P., Goldman, R., Sullivan, P., Walker, G. F. et al., Heteronuclear NMR-studies of C-13-labeled yeast-cell wall beta-glucan oligosaccharides. *J. Biomol. NMR* 1993, 3, 429–441.
- [21] Lesage, G., Bussey, H., Cell wall assembly in *Saccharomyces cerevisiae*. *Microbiol. Mol. Biol. Rev.* 2006, 70, 317–343.
- [22] Jamas, S., Chen, Y. C. J., Vonderosten, C. H., Sinskey, A. J. et al., Spectral-analysis of glucan produced by wild-type and mutant *Saccharomyces cerevisiae*. *Carbohydr. Polym.* 1990, 13, 207–219.
- [23] Jamas, S., Rha, C. K., Sinskey, A. J., Glucan composition and process for preparation thereof. 1992, US Patent 5.082,936.
- [24] Rieder, A., Grimmer, S., L, Aachmann, F. L., Westereng, B. et al., Generic tools to assess genuine carbohydrate specific effects on in vitro immune modulation exemplified by β -glucans. *Carbohydr. Poly.* 2013, 92, 2075–2083.
- [25] Smythies, L. E., Sellers, M., Clements, R. H., Mosteller-Barnum, M. et al., Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. *J. Clin. Invest.* 2005, 115, 66–75.

- [26] Parham, P., *The Immune System*, Garland Science, Taylor & Francis Group, New York 2009.
- [27] Falch, B. H., Espevik, T., Ryan, L., Stokke, B. T., The cytokine stimulating activity of (1 → 3)-beta-D-glucans is dependent on the triple helix conformation. *Carbohyd. Res.* 2000, 329, 587–596.
- [28] Gawronski, M., Park, J. T., Magee, A. S., Conrad, H., Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle X-ray scattering. *Biopolymers* 1999, 50, 569–578.
- [29] Talbott, S., Talbott, J., Effect of beta 1, 3/1, 6 glucan on upper respiratory tract infection symptoms and mood state in marathon athletes. *J. Sport Sci. Med.* 2009, 8, 509–515.
- [30] Talbott, S., Talbott, J., Beta 1,3/1,6 glucan decreases upper respiratory tract infection symptoms and improves psychological well-being in moderate to highly-stressed subjects. *Agro Food Ind. Hi. Tec.* 2010, 21, 21–24.
- [31] Feldman, S., Schwartz, H. I., Kalman, D. S., Mayers, A. et al., Randomized phase II clinical trials of Wellmune WGP(R) for immune support during cold and flu season. *J. Appl. Res.* 2009, 9, 30–42.
- [32] Fuller, R., Butt, H., Noakes, P. S., Kenyon, J. et al., Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections. *Nutrition* 2012, 28, 665–669.
- [33] Graubaum, H.-J., Busch, R., Stier, H., Gruenwald, J., A double-blind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. *Food Nutr. Sci.* 2012, 3, 738–746.
- [34] Auinger, A., Riede, L., Bothe, G., Busch, R. et al., Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. *Eur. J. Nutr.* 2013, doi: 10.1007/s00394-013-0492-z.
- [35] Gleeson, M., Bishop, N., Oliveira, M., McCauley, T. et al., Respiratory infection risk in athletes: association with antigen-stimulated IL-10 production and salivary IgA secretion. *Scand. J. Med. Sci. Sports* 2012, 22, 410–417.
- [36] Mortatti, A. L., Moreira, A., Aoki, M. S., Crewther, B. T. et al., Effect of competition on salivary cortisol, immunoglobulin A, and upper respiratory tract infections in elite young soccer players. *J. Strength Cond. Res.* 2012, 26, 1396–1401.

[37] Nieman, D. C., Henson, D. A., Dumke, C. L., Lind, R. H. et al., Relationship between salivary IgA secretion and upper respiratory tract infection following a 160-km race. *J. Sports Med. Phys. Fitness* 2006, 46, 158–162.

[38] Phillips, A. C., Carroll, D., Evans, P., Bosch, J. A. et al., Stressful life events are associated with low secretion rates of immunoglobulin A in saliva in the middle aged and elderly. *Brain Behav. Immun.* 2006, 20, 191–197.

[39] Lehne, G., Haneberg, B., Gaustad, P., Johansen, P. W. et al., Oral administration of a new soluble branched β -1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. *Clin. Exp. Immunol.* 2005, 143, 65–69.

[40] Weiszarrington, P., Grimes, S. R., Lamm, M. E., Gut-associated lymphoid tissue as source of an IgA immune response in respiratory tissues after oral immunization and intrabronchial challenge. *Cell. Immunol.* 1987, 106, 132–138.

[41] Czerkinsky, C., Svennerholm, A. M., Quiding, M., Jonsson, R. et al., Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. *Infect. Immun.* 1991, 59, 996–1001.

[42] Kohl, A., Gogebakan, O., Mohlig, M., Osterhoff, M. et al., Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1,3)(1,6)-beta-glycan consumption in overweight humans. *Nutr. Res.* 2009, 29, 248–254.

[43] Aarsaether, E., Rydningen, M., Einar Engstad, R., Busund, R., Cardioprotective effect of pretreatment with beta-glucan in coronary artery bypass grafting. *Scand. Cardiovasc. J.* 2006, 40, 298–304.

[44] Kirmaz, C., Bayrak, P., Yilmaz, O., Yuksel, H., Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study. *Eur. Cyto. Network* 2005, 16, 128–134.

[45] Demir, G., Klein, H. O., Mandel-Molinas, N., Tuzuner, N., Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. *Int. Immunopharmacol.* 2007, 7, 113–116.

[46] Ueno, H., Beta-1,3-D-glucan, its immune effect and its clinical use. *Jap. J. Soc. Term. Syst. Dis.* 2000, 6, 151–154.

[47] Torello, C. O., de Souza Queiroz, J., Oliveira, S. C., Queiroz, M. L., Immunohematopoietic modulation by oral beta-1,3-glucan in mice infected with *Listeria monocytogenes*. *Int. Immunopharmacol.* 2010, 10, 1573–1579.

- [48] Vetvicka, V., Terayama, K., Mandeville, R., Brousseau, P. et al., Pilot study: orally-administered yeast β 1,3-glucan prophylactically protects against anthrax infection and cancer in mice. *JANA* 2002, 5, 5–9.
- [49] Sandvik, A., Wang, Y. Y., Morton, H. C., Aasen, A. O. et al., Oral and systemic administration of beta-glucan protects against lipopolysaccharide-induced shock and organ injury in rats. *Clin. Exp. Immunol.* 2007, 148, 168–177.
- [50] Zhu, W., Gu, B. B., Miao, J. F., Lu, J. Y. et al., Dectin1 activation of beta-(1-3)/(1-6)-D-glucan produces an anti-mastitis effect in rats. *Inflamm. Res.* 2011, 60, 937–945.
- [51] Tsukada, C., Yokoyama, H., Miyaji, C., Ishimoto, Y. et al., Immunopotential of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. *Cell. Immunol.* 2003, 221, 1–5.
- [52] Stuyven, E., Van den Broeck, W., Nauwynck, H., Goddeeris, B. M. et al., Oral administration of beta-1,3/1,6-glucan Macrogard (R) fails to enhance the mucosal immune response following oral F4 fimbrial immunisation in gnotobiotic pigs. *Vet. Immunol. Immunopathol.* 2010, 137, 291–297.
- [53] Vetvicka, V., Vancikova, Z., Anti-stress action of several orally-given beta-glucans. *Biomed. Pap.* 2010, 154, 235–238.
- [54] Baran, J., Allendorf, D. J., Hong, F., Ross, G. D., Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. *Folia. Histochem. Cytobiol.* 2007, 45, 107–114.
- [55] Qi, C. J., Cai, Y. H., Gunn, L., Ding, C. L. et al., Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. *Blood* 2011, 117, 6825–6836.
- [56] Harnack, U., Eckert, K., Pecher, G., Beta-(1–3),(1–6)-D-glucan enhances the effect of low-dose cyclophosphamide treatment on A20 lymphoma in mice. *Anticancer Res.* 2011, 31, 1169–1172.
- [57] Harnack, U., Eckert, K., Fichtner, I., Pecher, G., Oral administration of a soluble 1–3, 1–6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice. *Int. Immunopharmacol.* 2009, 9, 1298–1303.
- [58] Li, B., Cai, Y., Qi, C., Hansen, R. et al., Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. *Clin. Cancer Res.* 2010, 16, 5153–5164.

- [59] Hong, F., Yan, J., Baran, J. T., Allendorf, D. J. et al., Mechanism by which orally administered beta-1,3-glucans enhance tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. *J. Immunol.* 2004, 173, 797–806.
- [60] Bayrak, O., Turgut, F., Karatas, O. F., Cimentepe, E. et al., Oral beta-glucan protects kidney against ischemia/reperfusion injury in rats. *Am. J. Nephrol.* 2008, 28, 190–196.
- [61] Aarsaether, E., Straumbotn, E., Rosner, A., Busund, R., Oral beta-glucan reduces infarction size and improves regional contractile function in a porcine ischaemia/reperfusion model. *Eur. J. Cardio-thorac. Surg.* 2012, 41, 919–925.
- [62] Vetvicka, V., Vetvickova, J., Effects of glucan on immunosuppressive actions of mercury. *J. Medic. Food* 2009, 12, 1098–1104.
- [63] Sener, G., Eksioglu-Demiralp, E., Cetiner, M., Ercan, F. et al., Beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. *Eur. J. Pharmacol.* 2006, 542, 170–178.
- [64] Toklu, H. Z., Sehirli, A. O., Velioglu-Ogunc, A., Cetinel, S. et al., Acetaminophen-induced toxicity is prevented by beta-D-glucan treatment in mice. *Eur. J. Pharmacol.* 2006, 543, 133–140.
- [65] Babicek, K., Cechova, I., Simon, R. R., Harwood, M. et al., Toxicological assessment of a particulate yeast (1,3/1,6)-beta-D-glucan in rats. *Food Chem. Toxicol.* 2007, 45, 1719–1730.
- [66] Gebert, A., H.-J, R., Pabst, R., M cells in Peyer's patches of the intestine. *Internat. Rev. Cytol.* 1996, 167, 91–159.
- [67] Beier, R., Gebert, A., Kinetics of particle uptake in the domes of Peyer's patches. *Am. J. Physiol.* 1998, 275, G130–G137.
- [68] Hunter, K. W., Gault, R. A., Berner, M. D., Preparation of microparticulate beta-glucan from *Saccharomyces cerevisiae* for use in immune potentiation. *Lett. Appl. Microbiol.* 2002, 35, 267–271.
- [69] Rice, P. J., Adams, E. L., Ozment-Skelton, T., Gonzalez, A. J. et al., Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. *J. Pharmacol. Exp. Therap.* 2005, 314, 1079–1086.
- [70] Vetvicka, V., Dvorak, B., Vetvickova, J., Richter, J. et al., Orally administered marine (1–>3)-beta-D-glucan phycarine stimulates both humoral and cellular immunity. *Internat. J. Biol. Macromol.* 2007, 40, 291–298.
- [71] Tabata, Y., Ikada, Y., Effect of the size and surface-charge of polymer microspheres on their phagocytosis by macrophage. *Biomaterials* 1988, 9, 356–362.

[72] Goodridge, H. S., Reyes, C. N., Becker, C. A., Katsumoto, T. R. et al., Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. *Nature* 2011, 472, U471–U541.

[73] Ishibashi, K., Miura, N. N., Adachi, Y., Ogura, N. et al., Relationship between the physical properties of *Candida albicans* cell wall beta-glucan and activation of leukocytes in vitro. *Int. Immunopharmacol.* 2002, 2, 1109–1122.

[74] Winkler, P., Ghadimi, D., Schrezenmeir, J., Kraehenbuhl, J. P., Molecular and cellular basis of microflora-host interactions. *J. Nutr.* 2007, 137, 756s–772s.

[75] Gertsch, J., Viveros-Paredes, J. M., Taylor, P., Plant immunostimulants-scientific paradigm or myth? *J. Ethnopharmacol.* 2011, 136, 385–391.

[76] Terpstra, A. H. M., Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. *J. Nutr.* 2001, 131, 2067–2068.

[77] Samuelsen, Anne Berit C., Jürgen Schrezenmeir, and Svein H. Knutsen., Effects of orally administered yeast-derived beta-glucans: A review. *Molecular nutrition & food research* 58.1. 2014, 183-193.

[78] Danielson, Michael E., et al., Enzymatic method to measure β -1, 3- β -1, 6-glucan content in extracts and formulated products (GEM assay). *Journal of agricultural and food chemistry* 58.19. 2010, 10305-10308.

[79] Tsikitis, Vassiliki L., Jorge E. Albina, and Jonathan S. Reichner., β -glucan affects leukocyte navigation in a complex chemotactic gradient. *Surgery* 136.2. 2004, 384-389.

[80] Yan, Jun, Daniel J. Allendorf, and Brian Brandley., Yeast whole glucan particle (WGP) β -glucan in conjunction with antitumour monoclonal antibodies to treat cancer. 2005, 691-702.

[81] Allendorf, Daniel J., et al., C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and β -glucan. *The journal of Immunology* 174.11. 2005, 7050-7056.

[82] Cramer, Daniel E., et al., β -Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. *Blood* 107.2. 2006, 835-840.

[83] Li, Bing, et al., Yeast β -glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. *The Journal of Immunology* 177.3. 2006, 1661-1669.



[84] Lavigne, Liz M., Jorge E. Albina, and Jonathan S. Reichner., β -Glucan is a fungal determinant for adhesion-dependent human neutrophil functions. *The Journal of Immunology* 177.12. 2006, 8667-8675.

[85] Driscoll, Michael, et al., Therapeutic potential of various β -glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. *Cancer biology & therapy* 8.3. 2009, 218-225.

[86] Bose, Nandita, et al., Differential regulation of oxidative burst by distinct β -glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells. *Glycobiology*. 2014, cwu005.

[87] Scalabrin, Deolinda, et al., Formula with docosahexaenoic acid, prebiotics, and beta-glucan supports respiratory and skin health in children (382.6). *The FASEB Journal* 28.1 Supplement. 2014, 382-6.

[88] Li, Fei, et al., Follow-up formula consumption in 3-to 4-year-olds and respiratory infections: an RCT. *Pediatrics* 133.6. 2014, e1533-e1540.

[89] Fuller R.J., et al., Yeast-Derived 1,3/1,6 Glucopolysaccharide to Prevent Upper Respiratory Tract Infection and Modulate Circulating Cytokines and Chemokines in Older Adults. University of Southampton School of Medicine. 2014.

[90] Harger-Domitrovich, Stephanie G., Joseph W. Domitrovich, and Brent C. Ruby., Effects of an Immunomodulating Supplement on Upper Respiratory Tract Infection Symptoms in Wildland Firefighters 2001. *FACSM*. 2008.

[91] Talbott, Shawn M., et al., β -Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers. *Food Science & Nutrition* 1.1. 2013, 90-101.

[92] Talbott, Shawn M., and Julie A. Talbott., Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. *Journal of the American College of Nutrition* 31.4. 2012, 295-300.

[93] Carpenter, K. C., et al., Baker's yeast β -glucan supplementation increases monocytes and cytokines post-exercise: implications for infection risk? *British Journal of Nutrition* 109.03. 2013, 478-486.

[94] McFarlin, Brian K., et al., Baker's yeast beta glucan supplementation increases salivary IgA and decreases cold/flu symptomatic days after intense exercise. *Journal of dietary supplements* 10.3. 2013, 171-183.



[95] Waszkiewicz-Robak, Bozena. Spent Brewer's yeast and beta-glucans isolated from them as diet components modifying blood lipid metabolism disturbed by an atherogenic Diet. INTECH Open Access Publisher, 2013.

[96] Amulic, Borko, Christel Cazalet, Garret L. Hayes, Kathleen D. Metzler, and Arturo Zychlinsky. "Neutrophil Function: From Mechanisms to Disease." Annual Review of Immunology Annu. Rev. Immunol. (2012): 459-89

[97] Scientific Opinion on the Safety of 'yeast Beta-glucans' as a Novel Food Ingredient. Parma, Italy: European Food Safety Authority EFSA, 2011